Premium
Granulocyte—macrophage colony stimulating factor in acute non‐lymphocytic leukaemia
Author(s) -
FANIN R.,
BACCARANI M.
Publication year - 1994
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.1994.tb00834.x
Subject(s) - granulocyte macrophage colony stimulating factor , medicine , granulocyte , haematopoiesis , immunology , precursor cell , hematopoietic growth factor , macrophage , granulocyte colony stimulating factor , colony stimulating factor , myelodysplastic syndromes , cancer research , chemotherapy , in vitro , stem cell , cytokine , biology , bone marrow , microbiology and biotechnology , biochemistry
. Background. Granulocyte‐macrophage colony stimulating factor (GM‐CSF) is required to maintain and to regulate granulocyte and monocyte productions. It is potentially useful for accelerating and enhancing haemopoietic recovery and neutrophil function. Results. In acute non‐lymphocytic leukaemia (ANLL) the dependence of blast cells on GM‐CSF and its role in the development and maintenance of leukaemia are still poorly defined. In vitro exposure of fresh leukaemic blast cells to a wide range of concentrations of GM‐CSF leads to a stimulation of cell proliferation in the majority of cases but does not induce any detectable maturation. Conclusions. Granulocyte‐macrophage colony stimulating factor may be used in the management of ANLL and the myelodysplastic syndrome (MDS) with the aim of: (i) accelerating the recovery of normal haemopoiesis; (ii) increasing cell killing by chemotherapy; and (iii) inducing cell maturation. Therefore the application of GM‐CSF can potentially improve treatment outcome in ANLL and is worth testing in a clinical setting.